3.07

8.87% 0.25

After Hours: 3.07

Casi Pharmaceuticals Inc (CASI)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Casi Pharmaceuticals Inc stock is traded at $3.07, with a volume of 71,497. It is up +8.87% in the last 24 hours and down -25.85% over the past month. CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

Previous Close:

$2.82

Open:

$2.8

24h Volume:

71,497

Relative Volume:

1.70

Market Cap:

$47.47M

Revenue:

$22.06M

Net Income/Loss:

$-30.94M

P/E Ratio:

-1.0302

EPS:

-2.98

Net Cash Flow:

$-26.70M

1W Performance:

+14.13%

1M Performance:

-25.85%

6M Performance:

-14.37%

1Y Performance:

-54.11%

1-Day Range:

$2.75

$3.47

1-Week Range:

$2.50

$3.47

52-Week Range:

$2.05

$8.19

Casi Pharmaceuticals Inc Stock (CASI) Company Profile

Name

Casi Pharmaceuticals Inc

Sector

Healthcare (1173)

Industry

Biotechnology (668)

Phone

Address

Employee

243

Twitter

Next Earnings Date

2024-11-14

Latest SEC Filings

CASI's Discussions on Twitter

Compare CASI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CASI Casi Pharmaceuticals Inc	3.07	47.47M	22.06M	-30.94M	-26.70M	-2.24
VRTX Vertex Pharmaceuticals Inc	410.65	105.75B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	716.68	78.76B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	632.04	37.79B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	242.50	31.28B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.77	27.28B	3.30B	-501.07M	1.03B	-2.1146

Casi Pharmaceuticals Inc Stock (CASI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-18-21	Initiated	BTIG Research	Buy
Apr-26-21	Initiated	Mizuho	Buy
Oct-23-20	Initiated	Oppenheimer	Outperform
Sep-22-16	Initiated	Maxim Group	Buy
Oct-29-15	Resumed	H.C. Wainwright	Buy
Jun-23-15	Initiated	H.C. Wainwright	Buy

View All

Casi Pharmaceuticals Inc Stock (CASI) Latest News

01:23 AM

CASI Pharmaceuticals, Inc. Announces Clinical Hold of CID-103 for Antibody Mediated Rejection of Kidney Transplant - Marketscreener.com

01:23 AM

08:59 AM

CASI Pharmaceuticals Faces Clinical Hold on CID-103 by FDA - TipRanks

08:59 AM

Dec 19, 2024

CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE - The Eastern Progress Online

Dec 19, 2024

Dec 16, 2024

CASI Pharmaceuticals Faces Evomela® License Termination Dispute - TipRanks

Dec 16, 2024

Nov 26, 2024

The Market Doesn't Like What It Sees From CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Revenues Yet As Shares Tumble 34% - Simply Wall St

Nov 26, 2024

Nov 22, 2024

CASI Pharmaceuticals Insider Ups Holding By 65% During Year - Simply Wall St

Nov 22, 2024

Nov 17, 2024

CASI Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 17, 2024

Nov 15, 2024

Earnings Flash (CASI) CASI PHARMACEUTICALS Reports Q3 Revenue $7.8M - Marketscreener.com

Nov 15, 2024

CASI Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 15, 2024

CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results - AccessWire

Nov 15, 2024

CASI Pharma Q3 Revenue Jumps 96% QoQ to $7.8M Despite Wider Losses, Advances Pipeline | CASI Stock News - StockTitan

Nov 15, 2024

Nov 12, 2024